Loading
Life sciences · Journal article
Frontiers in Immunology · November 2, 2026
No summary has been generated for this record yet. What follows is drawn from its source metadata only.
Journal article.
No findings were extractable from the material analysed.
Safety was not reported in the material analysed. Check the source before drawing any conclusion about harm.
The source did not state who this applies to in practice.
Graded across the dimensions that decide whether you should act, each from what the source actually supports. There is no single score, and where a dimension was not assessed it says so.
This record has not been graded across any dimension yet. Treat the label above as provisional and read the source.
What is missing. This record has no bottom line, key findings, reported figures, evidence dimensions. That is a gap in the analysis, not a judgement about the study.
This narrative review adopts the gut-immune-brain axis as the core framework. Literature published 2010-2025 was retrieved from PubMed, Web of Science and ScienceDirect; landmark pre-2010 studies from top journals were also included. Literature was analyzed across five dimensions: metabolite synthesis-transport, intestinal immune regulation, central mediation, disease-pathology links and clinical translation. We elucidate how short-chain fatty acids, tryptophan metabolites and bile acids act as immune messengers to modulate neural homeostasis. Under physiological conditions, they maintain barrier integrity and central immune balance; when dysregulated, they trigger immune disturbance, blood-brain barrier damage and neuroinflammation, promoting Alzheimer’s disease, Parkinson’s disease, major depressive disorder and chronic insomnia. Moving beyond conventional gut-brain-axis reviews focused merely on gut-brain communication, this work highlights immunity as the critical intermediate node and constructs the cascade “gut microbial metabolites-immune regulation-neural homeostasis-disease”. We further summarize biomarker prospects and intervention strategies including dietary fiber, pre-/probiotics and fecal microbiota transplantation. Notably, an ICH-M10-aligned five-stage biomarker validation framework and a gut-brain-immune tri-culture microfluidic model are proposed, offering new directions for mechanistic research and precision therapy for neurological disorders.